2023年3月21日 · What is acute myeloid leukemia (AML)? Acute myeloid leukemia (AML) is a rare cancer that affects your bone marrow and blood. It typically happens when certain genes or chromosomes mutate (change). AML usually affects people age 60 and older, but it can also affect younger adults and children.

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. [1] . Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. [1] .

急性髓系白血病 （acute myeloid leukemia，AML），急性髓系白血病是一类异质性血液系统疾病,其发生和发展与造血干细胞的成熟分化障碍、恶性克隆有关。受累的白血病细胞出现增殖失控、分化障碍、细胞凋亡受阻、骨髓造血功能受损和衰竭。

急性骨髓性白血病（acute myeloid leukemia，AML）又稱急性髓系白血病、急性髓细胞性白血病（acute myelogenous leukemia），是一组源于髓系造血干细胞或祖细胞克隆增生形成的恶性肿瘤疾病，克隆性增生可以累及髓系中的一个系列、两个系列或全部系列（红系、髓系和巨 ...

2025年2月18日 · 2022年发表了WHO第五版和国际共识标准 (ICC)两套AML 分类系统，两者均整合了新的分子学结果，并突出了生物学定义的和临床相关的AML 亚型。 本文讨论了两个系统之间的异同，以及自引入这些分类以来所面临的挑战和吸取的教训。 值得注意的是，急性早幼粒细胞白血病 (APL) 通常与PML::RARA易位相关，是一种独特的临床病理学 AML 疾病，占 AML 的5%-10%。 APL的初始治疗通常为全反式维甲酸 (ATRA) +三氧化二砷 (ATO)，WBC>10K/μL的患 …

2024年12月10日 · The first 5 decades of research in acute myeloid leukemia (AML) were dominated by the cytarabine plus anthracyclines backbone, with advances in strategies including allogeneic hematopoietic stem cell transplantation, high-dose cytarabine, supportive care measures, and targeted therapies for the subs …

2024年12月13日 · 对于急性髓系白血病（AML），前50年的研究主要集中在阿糖胞苷联合蒽环类药物，并在策略方面取得了一定进展，包括异基因造血干细胞移植、大剂量阿糖胞苷、支持治疗措施和急性早幼粒细胞白血病患者的靶向治疗。 2017年是AML研究的转折点，此后已有12种不同机制的药物在美国获批治疗AML。 此外，口服decitabine-cedazuridine已获批作为骨髓增生异常综合征肠外去甲基化药物的生物等效替代药物，可用于AML治疗；Menin抑制剂、CD123抗体-药 …

2022年6月22日 · AML defined by mutations include AML with NPM1 and AML with CEBPA mutation. AML with NPM1 mutation can be diagnosed irrespective of the blast count, albeit again with emphasis on judicious...

2025年3月1日 · Background Acute myeloid leukemia (AML) is a prevalent malignancy of the hematologic system. Despite advancements in therapeutic approaches, significant heterogeneity and therapeutic resistance pose substantial challenges to treatment. Tumors driven by core transcription factors through super-enhancers can establish core transcriptional regulatory circuits (CRCs) that modulate oncogene ...

6 天之前 · Different from many solid tumors in which low enrichment of immune signatures is associated with worse clinical outcomes, such as breast cancer (He et al., 2018) and melanoma (Liu et al., 2021), the low enrichment of immune pathways is a positive prognostic factor in AML, as evidenced by the immune-deprived subtype (ImD) showing the highest ...